The company
BioAge Labs, Inc.
BIOA · Nasdaq
BIOA stood above a rising 150-day average in 39 of the last 51 weekly readings, and has been out of that trend for the last 11 weeks. It is 69.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 11
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $14.7M
- Officials’ trades on record
- 4
- Institutions holding
- 150 (+10)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 39 of 51 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
4 disclosed lines: House 4, Senate 0, executive 0; 1 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Suzan K. DelBene House: U.S. House ClerkWA01 | soldjoint | $1k–$15k | 9 Jun 2016filed 13 Jul 2016 |
| Suzan K. DelBene House: U.S. House ClerkWA01 | boughtjoint | $1k–$15k | 10 Oct 2014filed 20 Nov 2014 |
| Suzan K. DelBene House: U.S. House ClerkWA01 | boughtjoint | $1k–$15k | 9 Oct 2014filed 20 Nov 2014 |
| Suzan K. DelBene House: U.S. House ClerkWA01 | boughtjoint | $15k–$50k | 24 Jul 2014filed 17 Aug 2014 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Shane BartonPrincipal Accounting Officer | sold | 20,216at $25.19 | 30 Jun 2026filed 1 Jul 2026 |
| Shane BartonPrincipal Accounting Officer | sold | 42,350at $25.21 | 29 Jun 2026filed 1 Jul 2026 |
| Paul D. RubinChief Medical Officer | sold | 8,820at $17.81 | 1 Apr 2026filed 3 Apr 2026 |
| Paul D. RubinChief Medical Officer | sold | 7,433at $20.30 | 2 Mar 2026filed 3 Mar 2026 |
| Paul D. RubinChief Medical Officer | sold | 7,433at $18.75 | 2 Feb 2026filed 3 Feb 2026 |
| Dov A. Md GoldsteinChief Financial Officer | sold | 8,974at $18.43 | 13 Jan 2026filed 15 Jan 2026 |
| Dov A. Md GoldsteinChief Financial Officer | sold | 4,440at $19.45 | 13 Jan 2026filed 15 Jan 2026 |
| Dov A. Md GoldsteinChief Financial Officer | sold | 11,663at $20.54 | 13 Jan 2026filed 15 Jan 2026 |
| Dov A. Md GoldsteinChief Financial Officer | sold | 1,923at $21.08 | 13 Jan 2026filed 15 Jan 2026 |
| Kristen FortneyChief Executive Officer | sold | 233,107at $18.12 | 13 Jan 2026filed 15 Jan 2026 |
| Paul D. RubinChief Medical Officer | sold | 7,433at $12.85 | 2 Jan 2026filed 6 Jan 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| a16z Capital Management, L.L.C.unchanged · filed 14 Aug 2026 | 3,233,170$79.2M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 2,849,077$69.8M | +581,321+25.6% |
| Cormorant Asset Management, LPreduced · filed 14 Aug 2026 | 2,390,605$58.6M | -500,000−17.3% |
| Sofinnova Investments, Inc.unchanged · filed 14 Aug 2026 | 2,293,788$56.2M | 00.0% |
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 2,144,633$52.6M | +2,144,633 |
| Octagon Capital Advisors LPunchanged · filed 14 Aug 2026 | 1,748,000$42.8M | 00.0% |
| RA CAPITAL MANAGEMENT, L.P.added · filed 14 Aug 2026 | 1,671,648$41.0M | +21,000+1.3% |
| MPM BIOIMPACT LLCnew · filed 14 Aug 2026 | 1,667,661$40.9M | +1,667,661 |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 1,544,214$37.8M | +189,308+14.0% |
| Polar Capital Holdings Plcreduced · filed 14 Aug 2026 | 1,072,344$26.3M | -60,296−5.3% |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.